Advances in Hematology

Research Article

IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch

Table 3

IL-31 and IL-8 serum levels in patients with CTCL and healthy controls.


	sIL-31 (pg/ml)	P (CTCL vs. C)	P (CTCL) †	sIL-8 (pg/ml)	P (CTCL vs. C)	P (CTCL) †

Controls (n = 29)	7.8 (0.3–55.3)	NA	NA	9.3 (3.4–52.0)	NA	NA
CTCL (n = 27)	24.2 (0.6–253.6)	0.012	NA	11.1 (3.4–322.5)	0.863	NA
MF (n = 17)	11.4 (0.6–58.6)	0.333	0.004	11.1 (3.4–31.2)	1.000	0.639
SS (n = 10)	28.3 (17.3–253.6)	<0.001	0.004	13.0 (4.2–322.5)	0.740	0.639
SC ≤ 5% lymphocytes (n = 17)	11.4 (0.6–253.6)	0.322	0.008	10.1 (3.4–31.2)	0.802	0.334
SC >5% lymphocytes (n = 10)	28.3 (17.3–209.1)	<0.001	0.008	18.3 (4.2–322.5)	0.495	0.334
SC < 1000/μl (n = 22)	21.9 (0.6–253.6)	0.070	0.138	10.7 (3.4–31.2)	0.581	0.033
SC ≥ 1000/μl (n = 5)	28.3 (17.3–60.6)	0.003	0.138	30.1 (6.0–322.5)	0.056	0.033
Stages I + II (n = 18)	12.2 (0.6–253.6)	0.212	0.026	9.3 (3.4–31.2)	0.991	0.596
Stages III + IV (n = 9)	28.3 (17.3–209.1)	<0.001	0.026	15.8 (4.2–322.5)	0.736	0.596
Without itch (VAS 0) (n = 9)	11.4 (0.6–30.1)	0.430	0.021	9.3 (3.9–31.2)	0.783	0.743
With itch (VAS 1–10) (n = 18)	27.7 (1.4–253.6)	0.002	0.021	11.4 (3.4–322.5)	0.726	0.743
Mild/moderate itch (VAS 1–5) (n = 7)	7.8 (1.4–253.6)	0.749	0.037	8.2 (3.4–26.1)	0.253	0.056
Intense/severe itch (VAS 6–10) (n = 11)	28.3 (17.3–209.1)	<0.001	0.037	20.8 (4.2–322.5)	0.175	0.056

Results are presented as mean ± standard deviation and as median and (range) values. Values were rounded to one decimal point. C, controls; CTCL, cutaneous T-cell lymphomas; sIL-8, interleukin-8 serum levels; sIL-31, interleukin-31 serum levels, MF, Mycosis Fungoides; NA, not applicable; PB, peripheral blood; SC, Sézary cells; SS, Sézary syndrome; VAS, visual analogue scale. values obtained when the mentioned CTCL groups were compared to each other, including outliers: MF vs. SS, CTCL with ≤5% SC vs. CTCL with >5% SC (expressed as % of PB lymphocytes); CTCL with SC < 1000/μL vs. CTCL with SC ≥ 1000/μL in the PB; CTCL stages I + II vs. CTCL stages III + IV; CTCL without itch (VAS 0) vs. CTCL with itch (VAS 1–10); CTCL with mild/moderate itch (VAS 1–5) vs. CTCL with intense/severe itch (VAS 6–10).